dalteparin has been researched along with d-alpha tocopherol in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferguson, JJ | 1 |
| Dubinsky, V; Gentile, T; Gutiérrez, G; Junovich, G; Pasqualini, S; Sarto, A | 1 |
| Cetin, M; Gökce, M; Kuskonmaz, B; Tuncer, M; Uckan Cetinkaya, D | 1 |
3 other study(ies) available for dalteparin and d-alpha tocopherol
| Article | Year |
|---|---|
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Monoclonal; Aspirin; Benzamidines; Biphenyl Compounds; Cardiology; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Disease; Dalteparin; Defibrillators, Implantable; Double-Blind Method; Enalapril; Endothelial Growth Factors; Fatty Acids, Omega-3; Guanidines; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Laser Therapy; Lymphokines; Metoprolol; Multicenter Studies as Topic; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pyrrolidines; Randomized Controlled Trials as Topic; Simvastatin; Sodium-Hydrogen Exchangers; Stents; Sulfones; Thrombolytic Therapy; Ticlopidine; Tissue Plasminogen Activator; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vitamin E | 1999 |
Comparative immunological effect of anticoagulant and antioxidant therapy in the prevention of abortion in mice.
Topics: Abortion, Habitual; Abortion, Induced; Animals; Anticoagulants; Antioxidants; Enoxaparin; Female; Humans; Interleukin-6; Male; Mice; Mice, Inbred CBA; Placenta; Pregnancy; Treatment Outcome; Up-Regulation; Vascular Endothelial Growth Factor A; Vitamin E | 2011 |
Coexisting or underlying risk factors of hepatic veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients receiving prophylaxis.
Topics: Administration, Oral; Adolescent; Age Factors; Amphotericin B; Anticoagulants; Antifungal Agents; Busulfan; Child; Child, Preschool; Drug Therapy, Combination; Enoxaparin; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Incidence; Infant; Kaplan-Meier Estimate; Kidney Diseases; Male; Parenteral Nutrition, Total; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Turkey; Ursodeoxycholic Acid; Vitamin E; Young Adult | 2013 |